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Cancer cells couple heightened lipogenesis with
lipolysis to produce fatty acid networks that support
malignancy. Monoacylglycerol lipase (MAGL) plays
a principal role in this process by converting mono-
glycerides, including the endocannabinoid 2-arachi-
donoylglycerol (2-AG), to free fatty acids. Here, we
show that MAGL is elevated in androgen-indepen-
dent versus androgen-dependent human prostate
cancer cell lines, and that pharmacological or RNA-
interference disruption of this enzyme impairs pros-
tate cancer aggressiveness. These effects were
partially reversed by treatment with fatty acids or
a cannabinoid receptor-1 (CB1) antagonist, and fully
reversed by cotreatment with both agents. We
further show that MAGL is part of a gene signature
correlated with epithelial-to-mesenchymal transition
and the stem-like properties of cancer cells, support-
ing a role for this enzyme in protumorigenic metabo-
lism that, for prostate cancer, involves the dual
control of endocannabinoid and fatty acid pathways.
INTRODUCTION
Cancer cells display alterations in metabolism that provide
a biochemical foundation for tumors to progress in their etiology
(DeBerardinis et al., 2008a; Kaelin and Thompson, 2010). These
changes include aerobic glycolysis (Warburg, 1956), glutamine-
dependent anaplerosis (Deberardinis et al., 2008b; Kovacevic
and McGivan, 1983), and de novo lipid biosynthesis (Menendez,
2010). Each of these metabolic pathways appears to be impor-
tant for the transformation of cells from a noncancerous to
a cancerous state; however, much less is understood about
the metabolic pathways that confer the aggressive properties
observed in malignant cancers, such as high migratory and inva-
sive activity. Because most cancer deaths are related to cancer
malignancy and metastasis (Jemal et al., 2010), understanding
metabolic pathways that contribute to these pathogenic features846 Chemistry & Biology 18, 846–856, July 29, 2011 ª2011 Elsevier Lis critical to both disease diagnosis and treatment. We recently
discovered that monoacylglycerol lipase (MAGL) is elevated in
aggressive cancer cells and primary tumors, where this meta-
bolic enzyme regulates a fatty acid network that supports high
migratory, invasive, and protumorigenic activity (Nomura et al.,
2010).
MAGL also plays an important role in regulating endocannabi-
noid signaling in the nervous system and some peripheral
tissues, where it is responsible for degrading the endogenous
cannabinoid receptor (CB1 and CB2) ligand, 2-arachidonoylgly-
cerol (2-AG; C20:4 monoacylglycerol [MAG]) (Blankman et al.,
2007; Chanda et al., 2010; Dinh et al., 2002; Long et al., 2009;
Schlosburg et al., 2010). Because direct cannabinoid receptor
agonists have been shown to impair cell growth, tumorigenicity,
and metastasis (Caffarel et al., 2010; Guzma´n, 2003; Sarfaraz
et al., 2005), it is possible that, at least for certain cancer types,
MAGL could also support tumorigenicity by limiting the negative
impact of endocannabinoids on cancer cell growth. However, in
our studies to date with ovarian, breast, and melanoma cancer
cells, we have yet to uncover evidence that endocannabinoid
metabolism serves as a basis for the protumorigenic function
of MAGL (Nomura et al., 2010), which instead appears to be
due principally to the fatty acid products of this enzyme. Prostate
cancer cells have been shown to express significant levels of
cannabinoid receptors (Sarfaraz et al., 2005), as well as endo-
cannabinoids and their corresponding metabolic enzymes,
including MAGL (Bifulco et al., 2008; Chung et al., 2009; Endsley
et al., 2008; Fowler et al., 2010; Mimeault et al., 2003; Nithipati-
kom et al., 2004, 2005; Thors et al., 2010; Wang et al., 2008).
Cannabinoid receptor agonists have also been shown to impair
prostate cancer cell malignancy (Guzma´n, 2003; Sarfaraz
et al., 2005). Nonetheless, whetherMAGLplays a protumorigenic
role in prostate cancer and, if so, by what mechanism are ques-
tions that remain unanswered.
Here, we show that MAGL activity is elevated in androgen-
independent human prostate cancer cell lines, where it supports
migration and tumor growth through a mechanism that involves
dual control over tumor-suppressing endocannabinoid and
tumor-promoting fatty acid pathways. Furthermore, through
global transcriptional profiling of aggressive and nonaggressive
human cancer lines across several tumor types, we have foundtd All rights reserved
PC
3
D
U1
45
LN
Ca
P
0
2
4
6
8
10
0
2
4
6
8
10
0
50
100
150
JZL184    -   +  -   +    -   +
total C20:4 MAG
hydrolytic activity
MAGL 
activity
MAGL 
ABPP-MudPIT
n
m
o
l/m
g/
m
in
n
m
o
l/m
g/
m
in
sp
ec
tra
l c
ou
nt
s
C20:4 M AG
0
10
20
30
40
50
C16:0 M AG
0
30
60
90
120
C18:0 M AG
0
50
100
150
C18:1 M AG
0
20
40
60
80
C20:4 FFA
0
20
40
60
80
100
C16:0 FFA
0
1000
2000
3000
4000
5000
C18:0 FFA
0
1000
2000
3000
4000
5000
C18:1 FFA
0
1000
2000
3000
4000
ABPP
JZL184  -  +  -  +  -  +
PC
3
D
U1
45
LN
Ca
P P
C3
D
U1
45
LN
Ca
P
PC
3
D
U1
45
LN
Ca
P
monoacylglycerols (MAG)
free fatty acids (FFA)
JZL184  -  + JZL184  -  + JZL184  -  + JZL184  -  +
JZL184  -  + JZL184  -  + JZL184  -  + JZL184  -  +
>
>
MAGL
**
**
**
**
**
*
**
**
*
**
**
** **
**
250
150
100
75
50
37
25
kDa
A B
C
D
>
>
KIAA
1363
pm
ol
/1
0 
 c
el
ls
6
pm
ol
/1
0 
 c
el
ls
6
pm
ol
/1
0 
 c
el
ls
6
pm
ol
/1
0 
 c
el
ls
6
pm
ol
/1
0 
 c
el
ls
6
pm
ol
/1
0 
 c
el
ls
6
pm
ol
/1
0 
 c
el
ls
6
pm
ol
/1
0 
 c
el
ls
6
E F
G
lysophosphatidyl cholines (LPC)
H
Figure 1. MAGL Is Elevated in Androgen-
Independent Prostate Cancer Cells Where
It Regulates MAG and FFA Metabolism
(A) ABPP analysis of serine hydrolase activities in
the androgen-dependent LNCaP and androgen-
independent PC3 and DU145 cell lines. Serine
hydrolase activities were labeled in whole-cell
proteomes with the activity-based probe FP-
rhodamine and detected by SDS-PAGE and in-gel
fluorescence scanning (fluorescent gel shown in
gray scale). MAGL and KIAA1363 are elevated in
PC3 and DU145 cells compared to LNCaP cells.
Proteomes were also prepared from cancer cells
pretreated with DMSO or the selective MAGL
inhibitor JZL184 (1 mM, 4 hr in situ) to confirm the
identities of the 33 and 35 kDa bands as MAGL.
(B) The left panel shows C20:4 MAG hydrolytic
activity of cancer cells in the presence or absence
of JZL184 (1 mM, 4 hr in situ). The middle panel
shows MAGL-specific activity derived from sub-
tracting the JZL184-insensitive portion from total
MAG hydrolytic activity. The right panel shows
spectral counts for MAGL in proteomes treated
with FP-biotin and subjected to ABPP-MudPIT.
(C and D) Inhibition of MAGL by JZL184 (1 mM, 4 hr,
in situ) raises MAG (C) and lowers FFA (D) levels in
PC3 cells.
(E–H) JZL184-treated PC3 cells also show eleva-
tions in LPCs (E), and reductions in PAs (F), LPA
(G), and LPEs (H). *p < 0.05, **p < 0.01 PC3 or
DU145 versus LNCaP cells for (B) and JZL184-
treated versus DMSO-treated control groups for
(C) and (D).
Data are presented as mean ± standard error of
the mean (SEM); n = 4–5/group. See also Table
S1,Table S2, and Figure S1.
Chemistry & Biology
Monoacylglycerol Lipase Supports Prostate Cancerthat MAGL is part of a gene expression signature that contains
many markers of epithelial-to-mesenchymal transition (EMT)
and cancer stem cells (CSCs) (Mani et al., 2008; Polyak and
Weinberg, 2009). Several additional metabolic enzymes are
also found as part of this EMT/CSC signature, most of which,
interestingly, to our knowledge, have not yet been examined
for functional roles in cancer.
RESULTS
MAGLActivity Is Elevated in Aggressive HumanProstate
Cancer Cell Lines
In a recent activity-based protein-profiling (ABPP) analysis of
a panel of human cancer cell lines (Nomura et al., 2010), weChemistry & Biology 18, 846–856, July 29, 2011found that MAGL activity was higher in
aggressive compared to nonaggressive
breast, melanoma, and ovarian cancer
cells. Here, we performed a similar
ABPP experiment comparing the aggres-
sive (highly migratory and invasive)
androgen-independent human prostate
cancer lines PC3 and DU145 to the
less-aggressive (poorly migratory and
invasive) androgen-dependent prostate
cancer line LNCaP (Hoosein et al., 1991;Chang et al., 2011). Cell proteomes were treated with the
activity-based probes fluorophosphonate (FP)-rhodamine (Patri-
celli et al., 2001) and FP-biotin (Liu et al., 1999) for gel and mass
spectrometry (MS)-based detection of serine hydrolase activi-
ties, respectively. FP-rhodamine-labeled enzymes were visual-
ized by SDS-PAGE (Figure 1A), which identified MAGL and
KIAA1363/AADACL1, both migrating as doublets likely due to
alternative splicing (Karlsson et al., 2001) and glycosylation
(Jessani et al., 2002), respectively, as being elevated in PC3
and DU145 cells compared to LNCaP cells. The FP-rhodamine
labeling of both forms of MAGL was blocked by the selective
small molecule inhibitor JZL184 (Long et al., 2009) (1 mM), which
showed no detectable cross-reactivity with other serine hydro-
lase activities in PC3 or DU145 cells (Figure 1A). Substrateª2011 Elsevier Ltd All rights reserved 847
Table 1. ABPP-MudPIT Analysis of Serine Hydrolase Activities in Human Prostate Cancer Cell Lines
Protein
LNCaP PC3 DU145
Abbreviation Av SEM Av SEM Av SEM
Prolyl endopeptidase PREP 455 64 423 144 132 11
FASN fatty acid synthase FASN 1850 135 1324 111 1385 170
Acyl-protein thioesterase 1 LYPLA1a 81 5 21 8 55 1
Abhydrolase domain-containing protein 10 ABHD10 622 132 534 111 252 29
Acylamino acid-releasing enzyme APEH 571 45 642 88 196 32
Probable serine carboxypeptidase CPVL CPVLa 0 0 27 4 6 1
Platelet-activating factor acetylhydrolase 2 PAFAH2 19 6 22 4 25 4
Prolyl endopeptidase-like isoform C PREPL 63 13 98 12 145 25
Acyl-protein thioesterase 2 LYPLA2a 31 15 138 7 106 13
Platelet-activating factor acetylhydrolase IB
subunit gamma
PAFAH1B3 72 13 0 0 43 17
Dipeptidyl peptidase 9 DPP9a 50 8 445 45 244 24
Patatin-like phospholipase domain-containing protein 4 PNPLA4 49 14 42 3 15 3
Protein phosphatase methylesterase 1 PPME1 63 5 48 12 14 3
Palmitoyl-protein thioesterase 2 PPT2a 3 2 22 8 42 5
Uncharacterized protein ABHD12 ABHD12 109 23 107 19 107 19
Platelet-activating factor acetylhydrolase IB PAFAH1B2 60 23 101 14 66 31
Abhydrolase domain-containing protein 11 ABHD11a 258 26 136 17 89 17
Retinoid-inducible serine carboxypeptidase SCPEP1 121 33 47 14 63 5
Arylacetamide deacetylase-like 1 (KIAA1363) AADACL1a 58 15 373 59 593 107
Abhydrolase domain-containing protein 6 ABHD6 55 11 62 9 81 11
Tripeptidyl peptidase II TPP2 4 2 10 1 3 1
Prolylcarboxypeptidase PRCP 77 13 49 27 33 9
Retinoblastoma-binding protein 9 RBB9 9 5 10 3 1 0
Dipeptidyl peptidase 8 DPP8 9 3 16 3 23 11
Cathepsin A CTSA 12 5 8 0 17 2
Abhydrolase domain-containing protein FAM108A1 FAM108A1 7 3 8 2 31 9
Neuropathy target esterase PNPLA6a 46 11 211 27 106 22
Lysophospholipase-like protein 1 LYPLAL1 73 21 25 11 27 7
Presenilins-associated rhomboid-like protein PARL 8 3 8 1 9 2
Abhydrolase domain-containing protein FAM108B1 FAM108B1 12 6 31 10 51 9
BAT5 BAT5 28 7 20 3 20 3
Abhydrolase domain-containing protein 3 ABHD3 2 1 7 2 9 4
Sialate O-acetylesterase SIAEa 94 20 10 1 7 0
Isoamyl acetate-hydrolyzing esterase 1 IAH1 2 1 5 1 1 1
Sn1-specific diacylglycerol lipase beta DAGLB 6 2 20 1 10 1
Monoglyceride lipase (MAGL) MGLLa 11 2 54 14 116 24
Carboxylesterase 2 CES2 18 4 9 2 10 3
PNPLA8 89 kDa protein PNPLA8 15 3 11 2 2 0
Abhydrolase domain-containing protein 4 ABHD4 27 7 5 1 6 1
Butyrylcholinesterase BCHE 10 4 0 0 0 0
Uncharacterized protein LACTB LACTB 2 1 2 1 5 1
Lon protease LONP1 48 4 34 9 14 2
Fatty acid amide hydrolase 1 FAAHa 181 56 0 0 9 2
Urokinase plasminogen activator PLAU 0 0 1 0 16 4
Similar to Dipeptidyl-peptidase 2 precursor DPP7a 170 48 14 1 8 2
Dipeptidyl peptidase 4 DPP4 38 7 89 9 1 0
Acetylcholinesterase ACHE 0 0 4 1 1 1
Abhydrolase domain-containing protein 2 ABHD2 22 7 0 0 0 0
Chemistry & Biology
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Table 1. Continued
Protein
LNCaP PC3 DU145
Abbreviation Av SEM Av SEM Av SEM
Fatty acid amide hydrolase 2 FAAH2 6 2 0 0 0 0
Isoform 1 of Tissue-type plasminogen activator PLAT 0 0 9 2 0 0
Serine hydrolase activities were filtered for enzymes that displayed: (1) >10-fold higher spectral counts in FP-biotin-treated proteomes compared to
‘‘no-probe’’ control proteomes for at least one of the cancer cell lines examined, and (2) an average of six or more spectral counts for at least one of the
cancer cell lines examined. Data represent average values ± standard error of the mean (SEM) for three to four independent experiments per cell line.
Av, average. See also Table S1.
a Serine hydrolase activities that were significantly higher or lower in both PC3 and DU145 cells versus LNCaP cells (i.e., p < 0.01 for PC3 versus LNCaP
and DU145 versus LNCaP).
Chemistry & Biology
Monoacylglycerol Lipase Supports Prostate Cancerassays using C20:4 MAG confirmed that the total and JZL184-
sensitive portions of MAGL hydrolytic activity were significantly
higher in PC3 and DU145 compared to LNCaP cells (Figure 1B).
Notably, a substantial proportion of C20:4 MAG hydrolytic
activity in LNCaP cells (50%) was not sensitive to JZL184, indi-
cating that other serine hydrolases contribute to MAG hydrolysis
in these cells (see below).
Prostate cancer cell proteomes were next treated with FP-
biotin, and probe-labeled enzymes were enriched by avidin
chromatography, digestedwith trypsin, and the resulting peptide
mixture was analyzed by multidimensional liquid chromatog-
raphy (LC)-MS. This method, referred to as ABPP-MudPIT (Jes-
sani et al., 2005), identified more than 50 serine hydrolases in
prostate cancer cells (Table 1; see Table S1 available online).
Several of these enzymes, including MAGL (Figure 1B) and
KIAA1363, were elevated in activity in PC3 and DU145 cells rela-
tive to LNCaP cells, as measured by the semiquantitative
method of spectral counting (Liu et al., 2004). Additional serine
hydrolase activities that were higher in PC3 and DU145 cells
included CPVL, DPP9, LYPLA2, PNPLA6, and PPT2 (Table 1).
In contrast the serine hydrolase activities ABHD11, FAAH, LY-
PLA1, DPP7, and SIAEwere enriched in LNCaP. FAAH has previ-
ously been shown to possess C20:4 MAG hydrolytic activity and
could account for much of the JZL184-insensitive portion of this
activity in LNCaP cells (Endsley et al., 2008; Goparaju et al.,
1998).
These data, taken together, identified several hydrolytic
enzymes with altered activities in aggressive versus nonaggres-
sive prostate cancer cells. Recent studies have uncovered a pro-
tumorigenic role for KIAA1363 in PC3 and DU145 cells (Chang
et al., 2011). Here, we asked whether MAGL also supports the
aggressiveness of these prostate cancer cell lines and, if so,
by what mechanism.
Metabolic Effects of Disrupting MAGL Activity
in Prostate Cancer Cells
We previously found that MAGL regulates not only MAGs but
also free fatty acids (FFAs) in aggressive breast, melanoma,
and ovarian cancer cells (Nomura et al., 2010). Consistent with
these findings, acute pharmacological blockade of MAGL in
PC3 and DU145 cells also led to elevations in several MAGs,
including C20:4, C16:0, C18:0, and C18:1, and reductions in
the corresponding FFAs (Figures 1C and 1D; Figure S1 and Table
S2).With the exception of C20:4 FFA andMAG, themagnitude of
the reductions of FFAs greatly exceeded the correspondingChemistry & Biology 18,elevations inMAGs.We performed an untargeted lipidomic anal-
ysis of JZL184-treated versus DMSO-treated PC3 cells, and
found that this discrepancy could partly be explained by
JZL184-induced elevations in not only MAGs but also lysophos-
phatidyl choline (LPC) levels (Figure 1E; Table S2). The cumula-
tive magnitude of elevation of MAGs and LPC (5 nmol) matched
closely the reduction in the corresponding FFAs (7 nmol) (Table
S2), suggesting that MAGs are shunted to LPC in cancer cells
where MAGL has been inactivated. These results are consistent
with our previous studies showing that metabolically labeled
MAGs are directly converted to LPCs by cancer cells through
a pathway that is greatly enhanced by MAGL inhibition (Nomura
et al., 2010). Our lipidomic analysis also revealed not only reduc-
tions in FFAs but also decreases in several additional metabo-
lites, including the protumorigenic signaling lipids, lysophospha-
tidic acid (LPA) (Mills and Moolenaar, 2003), phosphatidic acid
(PA) (Foster, 2009), and lysophosphatidyl ethanolamines (LPEs)
(Park et al., 2007) (Figures 1F–1H;Figure S1 and Table S2). These
bioactive lipids have been found to promote various aspects of
cancer aggressiveness, including migration, invasion, and
survival by signaling onto their cognate G protein-coupled
receptors (Foster, 2009; Mills and Moolenaar, 2003; Park et al.,
2007).We next generated stable small hairpin (sh)RNA-mediated
knockdown of MAGL using two independent probes (shMAGL1
and shMAGL2), both of which reduced MAGL activity by >75%
in PC3 cells (Figures 2A and 2B), and also caused significant
elevations in MAGs (Figure 2C) and corresponding reductions
in FFAs (Figure 2D). Lipidomic analysis of shControl versus
shMAGL PC3 cells also showed not only elevations in MAGs
and reductions in FFAs but also decreases in LPA, PA, and
LPE (Figure 2E; Figure S1 and Table S2). We also found that,
although acute JZL184 treatment elevated LPCs in PC3 cells,
this increase was not observed upon chronic JZL184 treatment
(4 days, 1 mM JZL184), revealing metabolic differences between
acute versus chronic blockade of MAGL and possible incorpora-
tion of transiently elevated LPCs into the more abundant phos-
phatidyl choline pools (Figure S1). We also observed similar
decreases in LPA and PA in DU145 cells treated with JZL184
(1 mM, 4 hr) (Figure S1 and Table S2). These results mirror the
metabolic effects of MAGL disruption in aggressive ovarian
and melanoma cancer cells (Nomura et al., 2010). On the other
hand, other changes observed in shMAGL ovarian and mela-
noma cancer cells, such as reductions in prostaglandins,
LPCs, and monoalkylglycerol ethers, were either unchanged or
not detected in PC3. Thus, MAGL ablation in prostate cancer846–856, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 849
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Figure 2. Stable shRNA-Mediated Knockdown of
MAGL Lowers FFA Levels in PC3 Cells
(A) MAGL was stably knocked down using two indepen-
dent short-hairpin RNA (shRNA) oligonucleotides
(shMAGL1 and shMAGL2), resulting in >75% reduction in
MAGL activity in PC3 cells, as assessed by ABPP analysis
of PC3 soluble proteomes, compared to shControl cells
expressing an shRNA that targets a distinct serine
hydrolase (DPP4).
(B) Measurements of C20:4 MAG hydrolytic activity for
whole-cell proteomes from parental, shControl, and
shMAGL (shMAGL1 and shMAGL2) PC3 cells show that
shMAGL cells exhibit significantly reduced MAGL activity.
(C and D) shMAGL cells show elevations in MAGs (C) and
reductions in FFAs (D). The MAGL activity and MAG and
FFA levels of shControl cells did not differ significantly
from those of parental cancer cell lines.
(E) Lipidomic analysis of PC3 shMAGL versus shControl
cells shows not only elevations in MAGs and reductions
in FFAs but also lower levels of LPEs, PAs, and LPA.
*p < 0.05, **p < 0.01 for shMAGL versus shControl groups.
Data are presented as mean ± SEM; n = 4–5/group. See
also Figure S1.
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Monoacylglycerol Lipase Supports Prostate Cancercells leads to reductions in cellular FFA levels and downstream
FFA-derived protumorigenic phospholipid signals. These results
are consistent with our previous study showing that isotopically
labeled FFAs in cancer cells are rapidly incorporated into phos-
pholipid species such as LPA, PA, and LPEs (Nomura et al.,
2010).
Disruption of MAGL Activity Impairs Cancer
Aggressiveness
shMAGL PC3 cells showed significant reductions in migration
(Figure 3A), invasion (Figure 3B), and survival (Figure 3C). Similar
effects were observed for PC3 (Figures 3D–3F) and DU145 (Fig-
ure S1) cells treatedwith JZL184 (1 mM, 4 hr). These data indicate
that disrupting MAGL reduces prostate cancer cell aggressive-
ness in vitro. We next asked whether blocking MAGL would
also impair the tumor growth of prostate cancer cells in vivo
using a mouse xenograft model. shMAGL PC3 cells displayed
significantly reduced tumor growth rates compared to control
PC3 cell lines in immune-deficient SCID mice (Figure S2). Daily
administration of JZL184 (40mg/kg, oral gavage) was also found
to slow PC3 tumor growth in this model (Figure 3G). Curiously,850 Chemistry & Biology 18, 846–856, July 29, 2011 ª2011 Elsevier Ltd All rights resewe did not observe an effect of JZL184 on tumor
growth when PC3 cells were placed in a nude
mouse xenograft model (Figure S3). Analysis
of excised tumors revealed that, whereas
JZL184 completely blocked MAGL activity in
tumors grown in SCID mice, this compound
only produced a partial inhibition of MAGL in
tumors grown in nude mice (Figure S3). We
also confirmed by assessing MAG hydrolytic
activity that MAGL was more completely in-
hibited in brain tissue from SCID versus nude
mice treated acutely with JZL184 (40 mg/kg, 4
and 24 hr) (Figure S3). Thus, incomplete MAGL
blockade could explain the lack of efficacy for
JZL184 in tumor xenograft models performedin a nude mouse background. We also cannot exclude the
possibility that the distinct effect on tumor growth in SCID versus
nude mice could be due to inherent biological differences
between the two mouse strains, such as immune cell leakiness
(Bankert et al., 2002; Sharkey and Fogh, 1984), which could
also inform on possible mechanisms of JZL184 anticancer
activity in vivo.
We previously found that overexpressing MAGL in nonaggres-
sive melanoma and ovarian cancer cells was sufficient to
reduce MAGs, elevate FFAs, and confer heightened pathoge-
nicity (Nomura et al., 2010). Therefore, we overexpressed
MAGL in LNCaP cells (MAGL-OE cells) to determine whether
we could mirror these effects in prostate cancer cells (Figure S4).
Although MAG levels were significantly reduced in MAGL-OE
LNCaP cells, FFA and phospholipid levels and migration were
unaltered. Although we do not yet understand why MAGL
is incapable of controlling FFAs in LNCaP cells, we found
that these cells express much higher levels of carnitine palmi-
toyltransferase 1 (CPT1), the rate-limiting step for fatty acid
b-oxidation, compared to DU145 and PC3 cells (Figure S4
and Table S3). It is possible that FFAs generated by LNCaPrved
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Figure 3. Pharmacological and shRNA
Blockade of MAGL Impairs PC3 Cell
Aggressiveness
(A–F) Both shMAGL and JZL184 (1 mM) PC3 cells
show impairedmigration (A and D), invasion (B and
E), and serum-free survival (C and F). Cancer cells
were pretreated with JZL184 in serum-free media
for 4 hr before migration (5 hr migration time) and
invasion (24 hr invasion time) assays and 24 hr
before cell survival (20 hr in serum and 4 hr in
serum-free media with JZL184). For PC3 migra-
tion, representative fields of migrated cells are
shown at 2003 magnification.
(G) Pharmacological (40 mg/kg JZL184, daily oral
gavage) inhibition of MAGL causes impairments in
PC3 tumor xenograft growth in immune-deficient
SCID mice. Representative tumors are shown on
the right. **p < 0.01 for shMAGL versus shControl
or JZL184 versus vehicle treatment groups.
Data are presented as mean ± SEM. For (A), (B),
(D), and (E), there are n = 4–5/group, and for (C), (F),
and (G), there are n = 6–8/group. See Figures S2
and S3.
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Monoacylglycerol Lipase Supports Prostate Cancercells overexpressing MAGL may be shunted into the mitochon-
dria via CPT1 to oxidative pathways, thereby preventing their
accumulation.
In our previous studies we found that the reduced migratory
activity of shMAGL breast, melanoma, and ovarian cancer cells
could be fully rescued by fatty acids, but not cannabinoid
receptor antagonists (Nomura et al., 2010), suggesting that the
fatty acid products of MAGL, rather than its endocannabinoid
substrates, were responsible for affecting migration in these
cells. Here, we uncovered a distinct mechanism in human pros-
tate cancer cells, where the migratory, invasion, and cell survival
defects caused by JZL184 or an shMAGL probe were only
partially reversed by treatment with palmitic acid (10 mM) (Fig-
ures 4A and 4B; Figure S4). Partial reversal was also observed
with the CB1 antagonist rimonabant (RIM) (1 mM), but not with
theCB2 antagonist AM630 (1 mM) (Figures 4A and 4B; Figure S4),
and a combination of palmitic acid and RIM fully restored migra-
tion in MAGL-disrupted prostate cancer cells (Figures 4A and
4B; Figure S4). We also found that PC3 migration was reduced
by treatment with the endocannabinoid 2-AG (1 mM) (Figure S4).
The partial rescue of the migratory activity of shMAGL cells
produced by palmitic acid was blocked by the Gi/o protein-Chemistry & Biology 18, 846–856, July 29, 2011uncoupling agent pertussis toxin (PTX;
100 ng/ml) (Figure S4), suggesting the
involvement of signaling lipids (such as
LPA, PA, and LPE) that act on G protein-
coupled receptors. Finally, the reduced
tumor growth of shMAGL cells in SCID
mice was also partially reversed by
RIM or a high-fat diet (HFD), and fully
restored by cotreatment of RIM and
a HFD (Figure 4C). These data indicate
that MAGL supports prostate cancer
aggressiveness by multiple mechanisms:
(1) the production of protumorigenic fattyacid products, and (2) the degradation of antitumorigenic
endocannabinoids.
MAGL Is Part of a Gene Signature that Contains EMT
and CSC Markers
Although we and others have shown that MAGL expression and
activity are elevated in aggressive human cancer cells and
primary tumors (Gjerstorff et al., 2006; Nomura et al., 2010), to
our knowledge, the pathways responsible for regulating MAGL
in cancer remain unknown. One strategy to map such pathways
would be to identify gene expression signatures that correlate
with MAGL activity in cancer cells. Toward this end, we tran-
scriptionally profiled sets of aggressive and nonaggressive
human cancer cell lines from four different tumor types (ovarian,
melanoma, breast, and prostate cancer) using Affymetrix
HU133 Plus 2.0 microarrays (Table S3). Consistent with our
ABPP results, MAGL expression was higher in all of the
aggressive cancer cell lines tested (SKOV3, C8161, 231MFP,
PC3, and DU145) compared to their nonaggressive counterparts
(OVCAR3, MUM2C, MCF7, and LNCaP). To uncover genes that
showed a similar expression pattern, we filtered the microarray
data sets to include only genes that displayed >3-fold higherª2011 Elsevier Ltd All rights reserved 851
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Figure 4. A Combination of Fatty Acid and CB1 Antag-
onist Rescues the Impaired Migration and Tumor
Growth of MAGL-Disrupted PC3 Cells
(A and B) The migratory defects observed with JZL184 (A) and
in shMAGL (B) PC3 cells are partially rescued upon cotreat-
ment with the CB1 antagonist RIM (1 mM) or palmitic acid
(10 mM) (denoted as FFA in the figure), and fully rescued upon
addition of both.
(C) Tumor growth defects observed with shMAGL PC3 cells
are also partially recovered upon daily administration of RIM
(3 mg/kg, oral gavage) or HFD (60 kcal-percent [%] diet) and
fully rescued with both. **p < 0.01 for shMAGL or JZL184
groups versus control or shControl groups; ## p < 0.01 for
JZL184 or shMAGL groups treated with RIM, FFA, and/or HFD
versus shMAGL or JZL184 groups.
Data are presented as mean ± SEM. For (A) and (B), there are
n = 4–5/group, and for (C), there are n = 5–8 mice/group. See
Figure S4.
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Monoacylglycerol Lipase Supports Prostate Cancersignals in at least four out of five sets of aggressive versus
nonaggressive cancer cells. This analysis identified 199 genes
that were consistently overexpressed in the aggressive cancer
cell line panel (Figure 5A; Table S3). Among these aggressive-
ness-correlated genes were numerous established markers of
EMT and CSCs, including VIM, TGFB1, CD44, LOX, LOXL2,
LAMB3, TGFBR2, ZEB1, LAMC2, EDN1, and EGFR (Polyak
and Weinberg, 2009) (Figure 5B; Table S3 and Table S4). We
identified 28 additional metabolic enzymes that were also part
of this aggressiveness gene signature, possibly pointing to other
metabolic pathways important for sustaining cancer malignancy
(Figure 5C; Table S3). A distinct set of metabolic enzymes
showed consistently lower expression in aggressive cancer lines
(Table S3), as did gene products known to be downregulated
following EMT (e.g., E-cadherin) (Polyak and Weinberg, 2009)
(Table S3). This large-scale transcriptional analysis suggests
that the heightened expression of MAGL (and several other
metabolic enzymes) in aggressive cancer cells may be due, at
least in part, to protumorigenic pathways that support EMT
and cancer ‘‘stemness.’’
DISCUSSION
Although MAGL has been most extensively studied for its role in
terminating endocannabinoid signaling in the nervous system
(Blankman et al., 2007; Dinh et al., 2002; Long et al., 2009;
Schlosburg et al., 2010), recent investigations have also pointed
to a function for this enzyme in cancer, where it regulates a set
of protumorigenic fatty acid products (Nomura et al., 2010).
Other components of the endocannabinoid system, including
the CB1 and FAAH, have also been implicated in cancer (Bifulco852 Chemistry & Biology 18, 846–856, July 29, 2011 ª2011 Elsevier Ltd All rights reet al., 2008; Chung et al., 2009; Endsley et al., 2008;
Fowler et al., 2010; Guzma´n, 2003; Mimeault et al.,
2003; Nithipatikom et al., 2004, 2005; Sarfaraz
et al., 2005; Thors et al., 2010; Wang et al., 2008).
Here, we have used ABPP analysis to determine
that MAGL and FAAH are highly expressed in
androgen-independent (PC3 and DU145) and
androgen-dependent (LNCaP) prostate cancer
cells, respectively. Because androgen-indepen-dent prostate cancer is the more malignant and life-threatening
form of this disease (Damber and Aus, 2008; So et al., 2005),
we sought to characterize the role that MAGL plays in PC3 and
DU145 cells.
Using a combination of selective inhibitors and shRNA probes,
we determined that MAGL exerts dual control over both endo-
cannabinoid and fatty acid pathways to support prostate cancer
aggressiveness. Through expressing high levels of MAGL
activity, androgen-independent prostate cancer cells limit the
inhibitory impact of endocannabinoid signaling and promote
the stimulatory effects of fatty acid pathways on protumorigenic
properties such as migration, invasion, and cell survival. This
mechanism for MAGL action in prostate cancer cells contrasts
with other types of cancer (e.g., ovarian, breast, and melanoma),
where endocannabinoid pathways were not found to play
a significant role in regulating aggressiveness (Nomura et al.,
2010). However, previous studies have shown that direct canna-
binoid receptor agonists impair the proliferation and metastatic
activity of cancer cells, as well as induce apoptosis in cancer
cells (Alexander et al., 2009; Guzma´n, 2003). These results indi-
cate that both exogenous and endogenous cannabinoids can
impede the progression of certain forms of cancer.
In addition to their direct effects on tumor cells, cannabi-
noids have been used in cancer treatment to alleviate many
of the side effects from chemotherapy, including nausea, vom-
iting, weight loss, lack of appetite, and pain (Guzma´n, 2003).
Although we do not know yet whether MAGL inhibitors will
impact all of these processes, they have been shown to exhibit
antiemesis (Sticht et al., 2011) and antihyperalgesic activity
(Kinsey et al., 2009; Long et al., 2009). Thus, MAGL inhibitors
have the potential to not only impair cancer progression butserved
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Figure 5. Gene Signatures of Aggressive Human
Cancer Cell Lines
(A) Transcriptional profiling of aggressive (noted in red,
PC3, DU145, C8161, SKOV, and 231MFP) versus nonag-
gressive (noted in blue, LNCaP, MUM2C, OVCAR3, and
MCF7) cancer cell lines yields commonly dysregulated
genes (left) (>3-fold changes in four out of five pairs of cell
lines).
(B) Several EMT and CSCmarkers are found among genes
consistently elevated in aggressive cancer lines.
(C) Metabolic enzymes consistently elevated (upper panel)
or reduced (lower panel) in aggressive cancer lines. Heat
maps were generated using Gene TreeView obtained from
http://rana.lbl.gov/EisenSoftware.htm. Blue versus white
denotes high versus low relative mRNA expression of each
gene, respectively. Relative mRNA expression, as ex-
pressed by blue color, was normalized to the highest DNA
microarray signal for each gene across the nine cancer cell
lines profiled.
See also Table S3.
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Monoacylglycerol Lipase Supports Prostate Canceralso remedy comorbidity factors, such as pain and nausea,
that accompany the treatment of this disease by more conven-
tional chemotherapeutics. In this regard we should also note
that MAGL inhibitors do not produce the cataleptic effects of
direct cannabinoid agonists and may, therefore, show an
improved safety profile (Long et al., 2009). On the otherChemistry & Biology 18, 846–856, July 29hand, recent studies indicate that complete
blockade of MAGL eventually leads to behav-
ioral tolerance that is accompanied by down-
regulation of CB1 in the nervous system
(Schlosburg et al., 2010). It remains to be
determined whether similar adaptations to
MAGL inhibition occur in cancer cells. It is
also of future interest to determine whether
the high FAAH expression in LNCaP cells
may point to a dual role of 2-AG and ananda-
mide in the control of androgen-dependent
prostate cancer biology. Further studies are
also required to determine whether MAGL is
elevated in primary human prostate tumors,
akin to its heightened expression in primary
breast and ovarian cancers (Gjerstorff et al.,
2006; Nomura et al., 2010).
We do not yet understand how MAGL is
elevated in aggressive cancer cells, but our
initial studies suggest that its heightened
expression is transcriptional in origin. Therefore,
we sought to identify an ‘‘aggressiveness’’-
associated gene signature that correlated with
MAGL across a panel of nine human cancer
cell lines originating from four different tumor
types (breast, melanoma, ovarian, and pros-
tate). This experiment revealed that aggressive
cancer cells possessing high levels of MAGL
also express numerous EMT and CSC markers,
many of which have been found to correlate
with, and contribute to, cancer malignancy
(Table S3 and Table S4). Interestingly, otherresearchers have similarly observed that cancer cells showing
the phenotypic hallmarks of EMT are enriched in stem cell
markers (Polyak and Weinberg, 2009). Moreover, recent studies
have found that MAGL is overexpressed in Ras-transformed
cancer cells along with other markers of EMT (Chun et al.,
2010; Joyce et al., 2009). These findings indicate that the, 2011 ª2011 Elsevier Ltd All rights reserved 853
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Monoacylglycerol Lipase Supports Prostate CancerMAGL-endocannabinoid/fatty acid pathway may constitute
a key metabolic network that supports EMT and the stem-like
properties of cancer cells. That several other metabolic
enzymes are also part of the aggressiveness gene signature
observed in this study points to fundamental differences in
the biochemistry of cancer cells that have undergone EMT
and stem-like conversion. Through our ABPP studies, we also
identified other serine hydrolase activities that are dysregulated
selectively in androgen-independent versus androgen-depen-
dent prostate cancer cells that may regulate additional meta-
bolic pathways that contribute to prostate cancer malignancy.
Future studies on MAGL and these aggressiveness-related
enzymes should increase our knowledge of the metabolic path-
ways that support cancer malignancy and identify new molec-
ular targets for cancer treatment.SIGNIFICANCE
Characterizing the metabolic pathways that tumor cells use
to support their malignant behavior is important for both
understanding and ultimately treating cancer. We have
previously shown that the lipolytic enzymeMAGL is elevated
in aggressive breast, ovarian, and melanoma cancer cells,
where it regulates a fatty acid network enriched in protu-
morigenic signaling lipids. Here, we show that MAGL is
also highly expressed in aggressive prostate cancer cells
where it not only regulates protumorigenic fatty acid prod-
ucts but also suppresses antitumorigenic endocannabinoid
signals. This dual control over fatty acid and endocannabi-
noid signaling pathways can be disrupted by inhibitors or
shRNA probes that target MAGL, resulting in impairments
in prostate cancer cell migration, invasion, survival, and
tumor growth. We also show that MAGL expression and
the expression of several othermetabolic enzymes correlate
with EMT and cancer stem cell markers across a broad
panel of human cancer cell lines. Thus, these data point to
a set of metabolic enzymes and pathways, such as the
MAGL-endocannabinoid/fatty acid network, thatmay create
key biochemical changes in cancer cells that support their
progression to a high-malignancy state. Disrupting these
pathways with small molecule inhibitors, as we show with
MAGL and its cognate inhibitor JZL184, could impair tumor
cell aggressiveness and offer novel ways to treat the most
aggressive forms of cancer.EXPERIMENTAL PROCEDURES
Materials
Prostate cancer cell lines LNCaP, PC3, and DU145 were obtained from ATCC.
OVCAR3, SKOV3, andMCF7 cell lines were obtained from the National Cancer
Institute’s Developmental Therapeutics Program. The C8161 and MUM2C
lines were provided by Mary Hendrix. The 231MFP cells were generated
from explanted xenograft tumors of MDA-MB-231 cells, as described previ-
ously (Jessani et al., 2004). The SKOV3 cells used in this study were also
derived from explanted xenograft tumors of SKOV3 cells. All lipid standards
and internal standards were purchased from Sigma, Alexis Biochemicals,
Cayman Chemicals, Nu-Chek Prep, or Avanti Lipids. FP-rhodamine (Patricelli
et al., 2001) and FP-biotin (Liu et al., 1999) were synthesized by following previ-
ously described procedures. RIM was purchased from AK Scientific. JZL184
was synthesized as previously detailed (Long et al., 2009).854 Chemistry & Biology 18, 846–856, July 29, 2011 ª2011 Elsevier LCell Culture
LNCaP, C8161, MUM2C, SKOV3, OVCAR3, and MCF7 cells were maintained
in RPMI medium, PC3 cells in F12K medium, DU145 cells in DMEM high-
glucose medium, and 231MFP in L-15 medium. All media were supplemented
with 4 mM L-glutamine and 10% (v/v) fetal calf serum and kept at 37C in
a humidified atmosphere of 5% CO2/95% air, except for 231MFP cells, which
were maintained in a CO2-free atmosphere.
For ABPP, activity assay, or lipidomic analysis, cells were treated as
described previously (Nomura et al., 2010). Briefly, 1 3 106 cells were plated
in 6 cm dishes (subconfluent). A total of 20 hr after plating, cells were washed
twice with phosphate-buffered saline (PBS), and inhibitors were incubated in
the corresponding serum-free media. For pharmacological treatments,
JZL184 (1 mM), RIM (1 mM), or FFA (10 mM), or vehicle (DMSO) at 0.1% was
incubated with the cells for 4 hr in serum-free media before cells were
harvested by scraping and analyzed by ABPP analysis or LC-MS. For chronic
JZL184 treatments, cells were treated once daily with JZL184 (1 mM) for 4 days
in serum-containing media. On the third day, DMSO or JZL184-treated cells
(1 3 106 cells) were seeded into 6 cm dishes and treated with DMSO or
JZL184. On the fourth day, cells were serum starved for 4 hr in the presence
of DMSO or JZL184, after which cells were washed twice with PBS, and
harvested by scraping.
ABPP Analysis of Cancer Cell Proteomes
ABPP analysis was performed as previously described (Nomura et al., 2010).
Briefly, cells were washed twice and scraped in ice-cold PBS. Cell pellets were
isolated by centrifugation at 1400 3 g for 3 min and sonicated in PBS. Either
whole-cell lysates or soluble proteomes were used for ABPP or MAG hydro-
lysis assays. To obtain soluble proteomes, cell lysates were centrifuged at
100,0003 g for 45min, and the supernatant was used for subsequent studies.
Protein concentrations were adjusted to a final concentration of 1 mg/ml in
PBS.
For gel-based ABPP experiments, cell lysate proteomes were treated with
2 mM FP-rhodamine for 30 min at room temperature before quenching reac-
tions with 1 vol of standard 43 SDS/PAGE loading buffer (reducing), separated
by SDS/PAGE (10% acrylamide), and visualized in-gel with a Hitachi FMBio IIe
flatbed fluorescence scanner (MiraiBio). Integrated band intensities were
calculated for the labeled proteins and averaged from three independent cell
samples to determine the level of each enzyme activity.
For MS-based ABPP experiments, cell lysate proteomes were treated with
5 mMFP-biotin for 1 hr at room temperature and processed as described previ-
ously (Nomura et al., 2010). After solubilization, avidin enrichment of FP-
labeled proteins, and on-bead tryptic digestion, digested peptide mixtures
were loaded onto a biphasic (strong cation exchange/reverse phase) capillary
column and analyzed by two-dimensional (2D) LC separation in combination
with tandem MS as previously described (Liu et al., 2004). Peptides were
eluted in a five-step MudPIT experiment (using 0%, 10%, 25%, 80%, and
100% salt bumps), and data were collected in an ion trap mass spectrometer,
LTQ (Thermo Scientific) set in a data-dependent acquisition mode with
dynamic exclusion turnedon (60 s). TheMS2spectral datawere searchedusing
the SEQUEST algorithm (Version 3.0) (Eng et al., 1994) against a custom-made
database containing the longest entry from v3.26 of the human IPI database
associated with each Ensembl gene identifier resulting in a total of 22,935
unique entries. Additionally, each of these entries was reversed and appended
to the database for assessment of false discovery rates.
Hydrolytic Activity Assays
Activity assays were performed as previously described (Nomura et al., 2010).
Briefly, cell lysates (20 mg) in PBSwere incubated with 100 mMof C20:4MAG at
room temperature for 30min in a volume of 200 ml before quenchingwith 600 ml
2:1 chloroform:methanol and subsequent addition of 10 nmol of C15:0 FFA
internal standard. The products were extracted into the organic layer, which
was removed and directly injected into LC-MS. LC-MS settings were as previ-
ously described (Blankman et al., 2007). Product levels (e.g., C20:4 FFA for
MAGL activity) were quantified in relation to internal standard levels.
RNA Interference Studies in Human Cancer Cell Lines
RNA interference studies were conducted as described previously (Chiang
et al., 2006; Nomura et al., 2010). Briefly, short-hairpin RNA constructstd All rights reserved
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Monoacylglycerol Lipase Supports Prostate Cancerwere subcloned into the pLP-RetroQ acceptor system, and retrovirus was
generated by using the AmphoPack-293 Cell Line (Clontech). Hairpin oligo-
nucleotides utilized were: for MAGL (shMAGL1), 50-CAACTTTCAAGGTCCT
TGC-30, and (shMAGL2), 50-AGACTACCCTGGGCTTCCT-30; for the shControl
(shDPPIV), 50-GATTCTTCTGGGACTGCTG-30. Infected cells were expanded
and tested for the loss of enzyme activity by ABPP and C20:4 MAG hydrolytic
activity.
Lipidomic Analysis of Prostate Cancer Cells
Lipidomic analyses were performed as previously described (Nomura et al.,
2010). Lipid measurements were conducted in cancer cells grown in serum-
free media for 4 hr to minimize the contribution of serum-derived lipids to
the cellular profiles. Cancer cells (1 3 106 cells/6 cm dish, 80% confluency)
were washed twice with PBS, isolated by centrifugation at 1400 3 g, and
metabolites were extracted and analyzed by MS using previously described
conditions (Nomura et al., 2010). Further details on lipidomic analyses are
provided in Supplemental Experimental Procedures.
Cell Migration, Cell Survival, and Invasion Studies
Migration, cell survival, and invasion studies of cancer cells were performed as
described previously (Nomura et al., 2010). Briefly, migration assays were per-
formed in Transwell chambers (Corning) with 8 mm pore-sized membranes
coated with 10 mg/ml collagen for 5 hr (for PC3) or 20 hr (for DU145 and LNCaP)
at 37C in serum-free media. The cells that migrated were counted at a magni-
fication of 4003, and four fields were independently counted from eachmigra-
tion chamber. An average of cells in four fields for one migration chamber
represents one replicate experiment. Cell survival assays were performed
using the Cell Proliferation Reagent WST-1 (Roche) as previously described
(Roca et al., 2008; Siddiqui et al., 2005) in cells serum starved 4 hr before
seeding. Invasion assays were conducted using the BD Matrigel Invasion
Chambers per the manufacturer’s protocol.
Tumor Xenograft Studies
Human cancer xenografts were established by transplanting cancer cell lines
ectopically into the flank of C.B17 SCID mice (Taconic Farms) or J/nu mice
(The Jackson Laboratory). Briefly, cells were washed two times with PBS,
trypsinized, and harvested in serum-containing medium. Next, the harvested
cells were washed two times with serum-free medium and resuspended at
a concentration of 2.0 3 104 cells/ml, and 100 ml was injected. Growth of the
tumors was measured every 3 days with calipers. For HFD studies, mice
were placed on a 60 kcal-percent (%) fat diet (Research Diets) 2 weeks prior
to cancer cell injections. For chronic JZL184 or RIM treatment studies, mice
were treated with JZL184 (40 mg/kg), RIM (3 mg/kg), or vehicle once daily
(at approximately the same time everyday) by oral gavage in polyethylene
glycol 300 (4 ml/g mouse). The treatments were initiated immediately after
ectopic injection of cancer cells.
DNA Microarray Comparisons of Aggressive versus Nonaggressive
Cancer Cell Lines
mRNAs were extracted (QIAGEN RNeasy Kit) from aggressive (231MFP,
SKOV3, C8161, PC3, and DU145) and nonaggressive (MCF7, OVCAR3,
MUM2C, LNCaP) cells from breast, ovarian, melanoma, and prostate cancers,
respectively, reverse transcribed, and hybridized to Affymetrix HU133 Plus 2.0
microarrays. Data were then filtered for genes that were commonly upregu-
lated or downregulated (>3-fold) in at least four out of the five pairs of aggres-
sive versus nonaggressive cancer cell lines for further analysis.
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